Stoke Therapeutics, Inc.
A biopharmaceutical company that aims to address the causes of serious diseases by enhancing protein expression with RNA-based drugs. The company is developing antisense oligonucleotide drugs that selectively restore protein levels, focusing on Dravet syndrome, a type of intractable epilepsy, and other central nervous system and ocular haploinsufficiencies. Based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | Massachusetts |
Employees | 110 |
Founded | 2014 |
Financials | |
|---|---|
Market Capitalization | 742.72M |
Revenue | 7.84M |
Operating Income | -118.45M |
Operating Margin | -1509.93% |
Net Income | -108.53M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4860 / 5373 |
Sector : Healthcare | 920 / 1144 |
Industry : Biotechnology | 478 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2675 / 5565 |
Sector : Healthcare | 362 / 1182 |
Industry : Biotechnology | 153 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4795 / 5436 |
Sector : Healthcare | 912 / 1164 |
Industry : Biotechnology | 478 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3953 / 5330 |
Sector : Healthcare | 608 / 1174 |
Industry : Biotechnology | 236 / 667 |